Global Digital Signature Market to Reach $2,934.6 Million by 2023     |    Global Outdoor Lighting Market to Witness 8.4% CAGR during 2017 - 2023     |    Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

Amyotrophic Lateral Sclerosis Pipeline Analysis, 2017

P&S Market Research-Amyotrophic Lateral Sclerosis Pipeline Analysis report

Amyotrophic Lateral Sclerosis Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: May 2017
Report Code: LS10963
Available Format: pdf
Pages: 118

Pipeline Overview

Amyotrophic lateral sclerosis is a disease that causes progression in neurodegeneration in brain and spinal cord. In Amyotrophic lateral sclerosis, the muscle does not get adequate nourishment due to which it becomes atrophic. The disease occurs in the lateral region, an area in which spinal cord reflexes are found majorly. Therefore, the degeneration leads to hardening and scarring of muscles in that region. The progressive degeneration of neurons from brain to the spinal cord and spinal cord to the whole body can ultimately lead to their death. The affected neurons in an individual can cause losing their ability to control muscles and performing other daily activities such as, ability to eat, move, breath, speak etc. Therefore, both voluntary and involuntary muscles tend to degenerate in Amyotrophic lateral sclerosis. The initial symptoms of the disease begin with losing control on the muscles that regulate the swallowing of food, speech and muscle of arms and legs, difficulty in lifting or grasping objects. Some of the other symptoms include muscle twitches and laughing or crying in an uncontrolled manner.

The growth in Amyotrophic lateral sclerosis therapeutic pipeline is mainly attributed to increase in development of innovative technologies and novel therapies. Various technologies such as Zydis ODT fast-dissolve technology and Q cells technology have helped in the development of therapies for the treatment of Amyotrophic lateral sclerosis. Gene therapies and cell therapies such as Q cells and VY-SOD101 are also adding to the development of therapeutic pipeline of Amyotrophic lateral sclerosis.

Pipeline Analysis

As of May 2017, the Amyotrophic lateral sclerosis pipeline comprises of approximately 69 drug candidates, out of which one drug candidate is in Phase III stage, 16 drug candidates are in Phase II stage, eight drug candidates are in Phase I stage, 32 drug candidates are in Pre-Clinical stage, five drug candidates are in inactive stage and six drug candidates are in discontinued drug candidates.

Many companies are developing Amyotrophic lateral sclerosis drug candidates in different phases. Cytokinetics, Inc., AB Science, F. Hoffman La-Roche AG, FlexPharma, Inc., Orion Corporation, Omeros Corporation, Genervon Biopharmaceuticals, LLC, Edison Pharmaceuticals, Inc., BrainStorm Cell Therapeutics, Inc. and various other companies have their Amyotrophic lateral sclerosis drug candidates in different stages of development. Cytokinetics, Inc. has drug candidate in Phase III clinical stage.

Biohaven Pharmaceutical Holding Company Ltd. is in the process of developing a novel compound, BHV-0223 which is a glutamate-modulating agent that utilizes the Zydis ODT fast-dissolve technology under an exclusive worldwide agreement with Catalent. Agents that modulate glutamate neurotransmission may have therapeutic potential in multiple disease states involving glutamate dysfunction, including ALS, ataxia, Alzheimer’s disease, Rett syndrome, dementia, dystonia, tinnitus, anxiety disorders, and affective disorders like major depressive disorder.



Amyotrophic Lateral Sclerosis Pipeline Analysis

Competitive Landscape

Several companies are involved in the development of Amyotrophic lateral sclerosis pipeline, with their products in different phases. AB Science has their drug candidate in the Phase III stage of development. F. Hoffman La-Roche AG, FlexPharma, Inc., Genervon Biopharmaceuticals, LLC have their drug candidates in Phase II stage of development. Genentech, Inc. has two drug candidates in Phase I stage of development. Neurimmune Therapeutics AG has three drug candidates in Pre-Clinical stage of development.

Some of the key players developing drugs for Amyotrophic lateral sclerosis include Genervon Biopharmaceuticals LLC, Orion Corporation, Genentech, Inc., Ono Pharmaceutical Co. Ltd., Biohaven Pharmaceutical Holding Company Ltd., Karyopharm Therapeutics Inc., Anelixis Therapeutics, LLC and Neurimmune Therapeutics AG.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

Group License

Group License authorizes access of the publication upto 5 users.

Site License

Site License authorizes access of the publication to all the employees of the organization at a single geographic location.

Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.


Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment